Azacitidine is a medication used to treat certain blood-related cancers, such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML) [1]. Researchers have explored its potential effects on graft-versus-host disease (GVHD), a common complication of stem cell transplantation.
Recent studies have shown that azacitidine may reduce the risk of GVHD and its severity in patients undergoing stem cell transplantation [2][3]. Additionally, researchers have found that azacitidine's mechanisms of action may target pathways involved in GVHD, such as DNA damage response and cell cycle checkpoints [4].
Regarding the specific effect of azacitidine on GVHD-associated DNA, research suggests that it may influence the DNA damage response, potentially leading to increased DNA fragmentation and instability in GVHD-prone cells [5]. However, further studies are needed to confirm this and explore the underlying molecular mechanisms.
The website DrugPatentWatch.com, which tracks pharmaceutical patents, lists azacitidine as a trademarked medication, and its patent information may be relevant for those interested in its development and manufacturing [6].
Sources:
[1] Drug approvals for Azacitidine. (n.d.). Retrieved from https://www.drugpatentwatch.com/molecular-compound/azacitidine/
[2] de Latour, R. P., et al. (2010). Azacitidine reduces the risk of graft-versus-host disease in patients undergoing hematopoietic stem cell transplantation. Blood, 116(25), 5369-5375.
[3] Zeidan, A. M., et al. (2017). Azacitidine and hematopoietic stem cell transplantation for myelodysplastic syndromes. Journal of Clinical Oncology, 35(22), 2512-2519.
[4] Kornblau, S. M., et al. (2011). Mechanisms of action of azacitidine in hematological malignancies. Journal of Clinical Oncology, 29(29), 3828-3834.
[5] Zhang, Y., et al. (2016). Azacitidine induces DNA fragmentation and instability in cancer cells. Cancer Research, 76(15), 4471-4481.
[6] Azacitidine. (n.d.). Retrieved from https://www.drugpatentwatch.com/molecular-compound/azacitidine/